Roche Announce Spinal Muscular Atrophy Agreement with PTC
Roche yesterday announced that they have signed a new licensing contract with PTC Therapeutics to develop treatments for a genetic muscle-weakening disease in a pact that could be worth $490 million. The Swiss major has signed up to gain access to PTC’s spinal muscular atrophy (SMA) programme. Â SMA is a genetic neuromuscular disorder that results